Humana Inc.
HealthcareNYSE:HUM · New York Stock Exchange
+$9.51 today
Vol 0.47M · Avg 1.73M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$137.2B of revenue converted into $1.1B of net income for the selected period. Gross margin is 14.0% and net margin is 0.7%, showing how much revenue survives after costs and taxes. EPS is $9.35, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $129.7B +10.1% | $117.8B +10.7% | $106.4B +14.5% | $92.9B +11.1% | $83.6B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $110.8B +10.1% | $100.7B +13.9% | $88.4B +16.8% | $75.7B +9.4% | $69.2B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $18.9B +9.9% | $17.1B -5.0% | $18.0B +4.7% | $17.2B +19.3% | $14.4B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 14.5% -0.0pp | 14.6% -2.4pp | 17.0% -1.6pp | 18.5% +1.3pp | 17.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $0 | $0 | $0 | $0 | $0 | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $17.4B +12.1% | $15.5B +5.4% | $14.7B +7.7% | $13.7B +23.9% | $11.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $824.0M -14.9% | $968.0M +5.6% | $917.0M +8.5% | $845.0M +18.5% | $713.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $2.9B -10.7% | $3.3B -31.2% | $4.7B -1.7% | $4.8B +7.9% | $4.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 2.2% -0.5pp | 2.8% -1.7pp | 4.4% -0.7pp | 5.2% -0.2pp | 5.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.5B -10.7% | $1.6B -51.0% | $3.3B -6.8% | $3.6B +4.2% | $3.4B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 1.1% -0.3pp | 1.4% -1.7pp | 3.1% -0.7pp | 3.8% -0.3pp | 4.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $631.0M -4.4% | $660.0M +33.9% | $493.0M +22.9% | $401.0M +23.0% | $326.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $0 | $0 | $0 | $0 | $0 | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.5B -10.7% | $1.6B -51.0% | $3.3B -6.8% | $3.6B +4.2% | $3.4B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 1.1% -0.3pp | 1.4% -1.7pp | 3.1% -0.7pp | 3.8% -0.3pp | 4.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $250.0M -39.5% | $413.0M -50.6% | $836.0M +9.7% | $762.0M +57.1% | $485.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.2B -1.6% | $1.2B -51.5% | $2.5B -11.3% | $2.8B -4.3% | $2.9B | $4.9B | $4.8B | $4.7B |
| Net Margin | 0.9% -0.1pp | 1.0% -1.3pp | 2.3% -0.7pp | 3.0% -0.5pp | 3.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $10 -1.4% | $10 -50.2% | $20 -9.5% | $22 -2.6% | $23 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $10 -1.4% | $10 -50.1% | $20 -9.4% | $22 -2.6% | $23 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $120.5M -0.1% | $120.6M -2.7% | $123.9M -2.0% | $126.4M -1.8% | $128.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $120.8M -0.0% | $120.9M -2.9% | $124.4M -2.1% | $127.1M -1.8% | $129.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Haleon plc
NYSE:HLN
$40.31B
Agilent Technologies, Inc.
NYSE:A
$36.55B
Alcon Inc.
NYSE:ALC
$32.51B
Centene Corporation
NYSE:CNC
$32.38B
IQVIA Holdings Inc.
NYSE:IQV
$29.87B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.50B
BeOne Medicines Ltd.
NASDAQ:ONC
$28.29B
ResMed Inc.
NYSE:RMD
$28.06B
Mettler-Toledo International Inc.
NYSE:MTD
$22.86B
Insmed Incorporated
NASDAQ:INSM
$21.25B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HUM generate?
Humana Inc. (HUM) reported $129.66B of revenue in fiscal 2025.
Is HUM profitable?
Humana Inc. (HUM) reported $1.19B of net income, with a net margin of 0.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.